Special Issue

Epidemiology of Clinically Relevant Bacteria and Antimicrobial Resistance

Message from the Guest Editor

Antimicrobial resistance (AMR) is a global concern, with increasing rates of multi-drug-resistant (MDR) pathogens reported clinically. Antibiotic resistance to last-line antibiotics including carbapenems, colistin and tigecycline is rising, as are reports of bacteria acquiring multiple plasmids or mobile genetic elements; thus multiple classes of antibiotics have been rendered ineffective. This Special Issue welcomes article submissions that feature clinically relevant bacteriology research and studies on antimicrobial resistance. Articles focusing on sepsis/blood stream infections or that cover a 'One Health Approach', including clinical samples or research from low-middle-income countries (LMICs), are particularly encouraged. Original research articles, review articles and method-based articles will be considered. Original research articles must include both epidemiological/clinical data and either phenotypic or genotypic profiling. Review articles must be centrally focused on antimicrobial resistance topics. Method articles must advance and/or focus on laboratory/informatics approaches relevant to antibiotic resistance research.

Guest Editor

Dr. Kirsty Sands

- Department of Biology, Ineos Oxford Institute, University of Oxford, Oxford OX13RE, UK
- Department of Medical Microbiology, Division of Infection and Immunity, Cardiff University, 6th Floor University Hospital of Wales, Cardiff CFI4 4XN. UK

Deadline for manuscript submissions

closed (31 August 2024)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/170363

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

